JP2024530170A5 - - Google Patents
Info
- Publication number
- JP2024530170A5 JP2024530170A5 JP2024506733A JP2024506733A JP2024530170A5 JP 2024530170 A5 JP2024530170 A5 JP 2024530170A5 JP 2024506733 A JP2024506733 A JP 2024506733A JP 2024506733 A JP2024506733 A JP 2024506733A JP 2024530170 A5 JP2024530170 A5 JP 2024530170A5
- Authority
- JP
- Japan
- Prior art keywords
- identity
- sequence
- sequence number
- bacteriophage
- polynucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163228504P | 2021-08-02 | 2021-08-02 | |
| US63/228,504 | 2021-08-02 | ||
| PCT/US2022/074446 WO2023015195A1 (en) | 2021-08-02 | 2022-08-02 | Bacteriophages with improved antimicrobial activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530170A JP2024530170A (ja) | 2024-08-16 |
| JP2024530170A5 true JP2024530170A5 (enExample) | 2025-08-13 |
Family
ID=85156425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506733A Pending JP2024530170A (ja) | 2021-08-02 | 2022-08-02 | 改善された抗微生物活性を有するバクテリオファージ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240352428A1 (enExample) |
| EP (1) | EP4380586A4 (enExample) |
| JP (1) | JP2024530170A (enExample) |
| KR (1) | KR20240042484A (enExample) |
| CN (1) | CN118591383A (enExample) |
| AU (1) | AU2022323171A1 (enExample) |
| CA (1) | CA3227846A1 (enExample) |
| IL (1) | IL310549A (enExample) |
| WO (1) | WO2023015195A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0300597D0 (en) * | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
| WO2011044279A2 (en) * | 2009-10-06 | 2011-04-14 | Bio Architecture Lab, Inc. | Microbial systems for producing commodity chemicals |
| CN113215115B (zh) * | 2014-12-16 | 2024-07-02 | C3J治疗公司 | 用于体外病毒基因组工程的组合物和方法 |
| US11421222B2 (en) * | 2019-06-18 | 2022-08-23 | Eligo Bioscience | Bacterial delivery vehicles comprising tracer nucleic acid sequences |
-
2022
- 2022-08-02 AU AU2022323171A patent/AU2022323171A1/en active Pending
- 2022-08-02 JP JP2024506733A patent/JP2024530170A/ja active Pending
- 2022-08-02 EP EP22854066.2A patent/EP4380586A4/en active Pending
- 2022-08-02 CA CA3227846A patent/CA3227846A1/en active Pending
- 2022-08-02 WO PCT/US2022/074446 patent/WO2023015195A1/en not_active Ceased
- 2022-08-02 KR KR1020247007051A patent/KR20240042484A/ko active Pending
- 2022-08-02 IL IL310549A patent/IL310549A/en unknown
- 2022-08-02 US US18/294,138 patent/US20240352428A1/en active Pending
- 2022-08-02 CN CN202280065190.8A patent/CN118591383A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Łusiak-Szelachowska et al. | Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far | |
| Łusiak-Szelachowska et al. | Bacteriophages and lysins in biofilm control | |
| Pereira et al. | Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B | |
| JP2023523319A5 (enExample) | ||
| EP4115897A1 (en) | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby | |
| Letkiewicz et al. | The perspectives of the application of phage therapy in chronic bacterial prostatitis | |
| Rice | Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria | |
| US12503687B2 (en) | Therapeutic bacteriophage compositions | |
| CN112218659A (zh) | 用于治疗葡萄球菌感染的治疗性噬菌体组合物 | |
| US20210187046A1 (en) | Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof | |
| Hong et al. | Optimizing in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multi-drug resistant Pseudomonas aeruginosa infections | |
| CN116018154A (zh) | 用于治疗假单胞菌属感染的噬菌体组合物 | |
| US20210361727A1 (en) | Bacteriophage compositions for treating pseudomonas infections | |
| Łusiak-Szelachowska et al. | Anti-biofilm activity of bacteriophages and lysins in chronic rhinosinusitis. | |
| ES2594901T3 (es) | Composición farmacéutica para el tratamiento de una enfermedad de las vías respiratorias | |
| EP3928782A1 (en) | Bacteriophage based therapy | |
| JP2024530170A5 (enExample) | ||
| Rezaei | Bacteriophages for the treatment of resistant bacterial infectious diseases | |
| JP2020524172A5 (enExample) | ||
| Selim et al. | Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens | |
| Grygorcewicz et al. | Bacteriophage‐based approach for treatment of urinary tract infections: a quick outlook | |
| CN104684924B (zh) | 含有主链环化肽的组合 | |
| Reyes et al. | Current perspectives: therapeutic uses of tobramycin | |
| Gonzalez‐Moreno et al. | Bacteriophages for Treatment of Biofilm Infections | |
| Babita et al. | Phage therapy reimagined: viral |